Navigation Links
Life Care Solutions Group: The #Vaginal Mesh Debacle Is More Complicated Then The Hip Settlement
Date:11/20/2013

CONCORD, Calif., Nov. 20, 2013 /PRNewswire/ -- The recently announced Johnson & Johnson Settlement for its defective metal-on-metal hip prosthetic implant will pay roughly $250,000 to each patient sustaining injuries related to this defective device. How this case compares to the 100,000 or so transvaginal mesh (#TVM) suits being filed against the various TVM manufacturers is open to debate. As a rehabilitation physician, life care planner, and attorney I will compare the two.

For a vast majority of patients sustaining injuries from the defective J & J hip replacement device, the medical remedy is a hip revision whereby the defective hip implant is removed and a new one is implanted. The pain caused by the defective hip prosthetic usually improves or resolves following this revision. Aside from the catastrophic complications that may occur from infection or fractures of the femoral shaft during revision surgery, the outcomes are generally good and fairly uniform. In addition, outcomes from hip revision surgery have been well studied in broad populations not involved in litigation. This means functional outcomes, life care costs, and future reasonable and appropriate medical care can be accurately testified to by experts in the field without the bias of litigation.

In the #transvaginal mesh debacle the injuries sustained, the functional outcomes, the medical treatment required, and the future reasonable and appropriate medical care that is necessary, is much more ill defined and variable compared to the defective hip situation.

The injuries caused by the transvaginal mesh debacle are more diverse than of the defective hip implant. Injuries from the mesh cause a variety of problems including erosions, recurrent infections, recurrent incontinence, recurrent prolapse, painful sexual intercourse related to pelvic myofascial pain, painful sexual intercourse related to pudendal neuralgia, ano-rectal pain related to pelvic myofascial pain, ano-rectal pain related to pudendal neuralgia, vulvodynia related to pelvic myofascial pain, vulvodynia related to pudendal neuralgia, and obturator neuralgia. All of these pain syndromes and functional problems may coexist and each patient is truly unique regarding how these pain generators affect mobility, sexual function, bowel evacuation, and bladder excretion.

The medical remedy for a mesh related complication is much less defined, poorly studied, and is developing as the mesh debacle unfolds. Remember, the most catastrophic complication of the transvaginal mesh debacle is pudendal neuralgia. This was such a rare complication prior to the defective TVM device that few physicians had either the knowledge to diagnose, or the skills to treat the condition. Best practice management of mesh related complications have recently been developed by the likes of Dr. Michael Hibner and clinicians across the country, who are proceeding with the best practice management of complete mesh removal if necessary for pain. Unfortunately, there are many women who have undergone partial mesh removal and experience ongoing pudendal neuralgia because the arms of the mesh are still retained in proximity to the pudendal nerve. Then there are women who continue to have the diverse symptoms of pudendal neuralgia and intractable pain without a definitive diagnosis, and without any available treatments. It is my opinion from talking to women across the country that just a small fraction of these most catastrophic patients have been referred for pudendal neurolysis, which is often necessary the treat the nerve damage.

Future reasonable and necessary medical care is also much more variable in the transvaginal mesh population. Future treatments include Botox, pudendal nerve block, ongoing physical therapy for #pudendal neuralgia or #myofascial pain, #pudendal neurolysis, revision #pudendal neurolysis, #ketamine for the #vulvadynia, #neuromodulation, #psychological treatments for pain and depression, and ongoing medications.

In the case of the defective hip replacement it is fairly easy to shape a reasonable settlement because of the relative uniformity among the plaintiffs. That is not the case in the transvaginal mesh client where each patient's symptoms, functional loss, and required treatment plan is absolutely unique.

Press release courtesy of Life Care Solutions Group: http://tvm.lifecare123.com/vaginal-mesh-debacle_11076.html

Media Contact

Lyn Giguere
Life Care Solutions Group
Lyn@Submitmypressrelease.com 
972-437-8952


'/>"/>
SOURCE Life Care Solutions Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First Financial Expands into Canada to Meet Increasing Demand for its Leasing Solutions
2. BioLife Solutions Appoints Raymond W. Cohen as Chairman and Joe Schick to Board of Directors
3. BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
4. Endo Health Solutions to Present at the 2013 Credit Suisse Healthcare Conference
5. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
6. HighPoint Solutions et InnoPeritus sassocient pour fournir des services consultatifs inédits sur le marché européen des sciences du vivant
7. HighPoint Solutions and InnoPeritus Partner to Provide Unprecedented Consultative Services in the European Life Sciences Market
8. Predilytics Launches Two Healthcare Analytics Solutions
9. mHealth Apps & Solutions Market - Global Trends & Forecast to 2018
10. Phonak Naida Q plus expanded Phonak Wireless Communication Portfolio: Powerful solutions for people with severe to profound hearing loss
11. Phonak pediatrics solutions ensure a childs speech access is continually optimized
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):